Executive Summary
The USA Bankruptcy & Insolvency intelligence stream highlights a single critical development: Zynex Inc.'s Chapter 11 reorganization plan confirmation on March 19, 2026, marking the culmination of proceedings initiated December 15, 2025, with emergence expected by March 31, 2026. All 30,781,021 existing common shares are cancelled with zero recovery for equity holders, transferring 100% ownership (approximately 1,000 new shares) to the Plan Sponsor and providing DIP Lenders $10M in takeback debt. No period-over-period financial trends are detailed in the filing, but the Nasdaq delisting (effective February 2, 2026) and OTC trading as ZYXIQ underscore speculative risks and total equity wipeout. Market implications include complete shareholder value destruction, heightened volatility in OTC trading, and a bearish sentiment (rated negative, materiality 10/10). Portfolio-level patterns are limited to this filing, but it exemplifies ongoing corporate insolvency pressures in the medical device sector, with no insider activity, capital allocation, or forward guidance beyond plan effectiveness noted.
Tracking the trend? Catch up on the prior US Bankruptcy Chapter 11 Insolvency SEC Filings digest from March 10, 2026.
Investment Signals(10)
- ZYNEX INC↓(BEARISH)▲
Third Amended Plan confirmed March 19, 2026, cancelling all 30,781,021 existing shares with no equity recovery
- ZYNEX INC↓(BEARISH)▲
Plan Sponsor receives 100% of ~1,000 new common shares post-emergence, wiping out prior shareholders
- ZYNEX INC↓(BEARISH)▲
DIP Lenders allocated $10M takeback debt, prioritizing creditors over equity in reorganization
- ZYNEX INC↓(BEARISH)▲
Nasdaq delisting via Form 25 effective February 2, 2026, after suspension December 24, 2025
- ZYNEX INC↓(BEARISH)▲
Stock now trades as ZYXIQ on OTC Markets with highly speculative nature and substantial investor risks
- ZYNEX INC↓(BEARISH)▲
Deregistration under Section 12(b) effective 90 days post-Form 25, eliminating SEC reporting obligations
- ZYNEX INC↓(BEARISH)▲
No period-over-period financial improvements cited leading to plan confirmation, signaling sustained distress
- ZYNEX INC↓(BEARISH)▲
Absence of insider buying or holdings retention amid bankruptcy, indicating zero management conviction
- ZYNEX INC↓(BEARISH)▲
No capital allocation for dividends, buybacks, or splits; equity fully cancelled
- ZYNEX INC↓(BEARISH)▲
Negative sentiment across filing with materiality 10/10, no bullish forward-looking elements beyond emergence
Risk Flags(8)
- ZYNEX INC / Equity Wipeout↓[HIGH RISK]▼
All 30,781,021 shares cancelled with no recovery, total loss for existing holders
- ZYNEX INC / Delisting↓[HIGH RISK]▼
Nasdaq delisting effective February 2, 2026, shifting to OTC ZYXIQ with illiquidity and volatility
- ZYNEX INC / Speculative Trading↓[HIGH RISK]▼
OTC trading highly speculative post-delisting, substantial risks for any investors
- ZYNEX INC / Ownership Transfer↓[HIGH RISK]▼
Plan Sponsor takes 100% of new shares, diluting prior stakeholders to zero
- ZYNEX INC / Creditor Priority↓[HIGH RISK]▼
$10M takeback debt to DIP Lenders, no equity participation for others
- ZYNEX INC / Regulatory Deregistration↓[HIGH RISK]▼
Section 12(b) deregistration 90 days post-Form 25, reduced transparency
- ZYNEX INC / Prolonged Insolvency↓[HIGH RISK]▼
Chapter 11 from December 15, 2025, to confirmation March 19, 2026, shows extended distress
- ZYNEX INC / No Operational Metrics↓[HIGH RISK]▼
Absence of positive YoY/QoQ trends or ratios in filing amid bankruptcy
Opportunities(8)
- ZYNEX INC / Plan Emergence↓(OPPORTUNITY)◆
Monitor effective date by March 31, 2026, for potential post-bankruptcy turnaround in medical devices
- ZYNEX INC / OTC Speculation↓(OPPORTUNITY)◆
High-risk trading in ZYXIQ for vulture investors betting on reorganization value unlock
- ZYNEX INC / Creditor Positions↓(OPPORTUNITY)◆
DIP Lenders' $10M takeback debt offers secured recovery in reorganized entity
- ZYNEX INC / Plan Sponsor Upside↓(OPPORTUNITY)◆
100% new shares to sponsor could attract distressed asset buyers pre-emergence
- ZYNEX INC / Short Equity↓(OPPORTUNITY)◆
Existing shareholders face certain cancellation; short ZYXIQ for speculative downside
- ZYNEX INC / Post-Delisting Arbitrage↓(OPPORTUNITY)◆
Potential price dislocations in OTC vs pre-delisting levels for traders
- ZYNEX INC / Sector Turnaround↓(OPPORTUNITY)◆
Bankruptcy exit may signal bottom in medical device insolvencies for relative value plays
- ZYNEX INC / Catalyst Timing↓(OPPORTUNITY)◆
Effective date <= March 31, 2026, as near-term event for position sizing
Sector Themes(5)
- Equity Annihilation in Insolvency(BEARISH SECTOR IMPACT)◆
1/1 filings show full common stock cancellation (30M+ shares), implying zero recovery norm in Chapter 11
- Delisting Cascade(BEARISH THEME)◆
Nasdaq delisting and OTC shift in 1/1 cases, increasing illiquidity and speculation in bankruptcy streams
- Creditor Dominance(NEUTRAL THEME)◆
DIP Lenders prioritized with $10M debt vs equity wipeout, highlighting debt-over-equity hierarchy in reorganizations
- Prolonged Chapter 11 Timelines(BEARISH THEME)◆
~3-month process from Dec 2025 filing to March 2026 confirmation, pressuring distressed sectors
- Negative Sentiment Uniformity(BEARISH THEME)◆
1/1 filings rated negative (10/10 materiality), no mixed signals in insolvency announcements
Watch List(7)
Plan effectiveness no later than March 31, 2026; monitor for emergence and new share issuance
Track volume and price volatility post-delisting for speculative moves
Section 12(b) effective ~May 2026 (90 days post-Feb 2); watch for transparency loss impacts
Observe sponsor's management of 100% new shares post-March 31, 2026
$10M takeback debt performance in reorganized entity; any amendments or defaults
Case No. 25-90810 updates from Southern District of Texas post-confirmation
Any new 13D/G activity from Plan Sponsor or lenders around emergence
Filing Analyses(1)
20-03-2026
Zynex, Inc. and certain subsidiaries had their Third Amended Combined Disclosure Statement and Joint Plan of Reorganization confirmed by the U.S. Bankruptcy Court for the Southern District of Texas on March 19, 2026, with an expected Effective Date no later than March 31, 2026, allowing emergence from Chapter 11 protection filed on December 15, 2025. However, the plan cancels all existing common stock (30,781,021 shares outstanding as of January 16, 2026) with no recovery for equity holders, while the Plan Sponsor receives 100% of approximately 1,000 new common shares and DIP Lenders get $10M in takeback debt. The company's stock was delisted from Nasdaq and now trades as ZYXIQ on OTC Markets, with trading highly speculative and substantial risks for investors.
- ·Bankruptcy case administered under In re Zynex, Inc., et al., Case No. 25-90810 in U.S. Bankruptcy Court for the Southern District of Texas.
- ·Nasdaq delisting notice received December 17, 2025; trading suspended December 24, 2025; Form 25 filed January 23, 2026, effective February 2, 2026.
- ·Deregistration of common stock under Section 12(b) effective 90 days after Form 25 filing.
- ·Plan filings: January 14, January 29, February 1, and February 7, 2026.
- ·Assets and liabilities as of September 30, 2025, referenced in Form 10-Q filed November 17, 2025.
Get daily alerts with 10 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 1 filings
🇺🇸 More from United States
View all →March 26, 2026
US Pre-Market SEC Filings Roundup — March 26, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
Biotech Small-Cap Approvals — March 25, 2026
Biotech Small-Cap Approvals
March 25, 2026
New Drug Approvals (Original) — March 25, 2026
New Drug Approvals (Original)